Orthofix Medical (NASDAQ:OFIX) Price Target Lowered to $17.00 at Barrington Research

Orthofix Medical (NASDAQ:OFIX) had its target price trimmed by Barrington Research from $18.00 to $17.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has an outperform rating on the medical device company’s stock.

OFIX has been the topic of a number of other research reports. TD Cowen began coverage on Orthofix Medical in a research note on Tuesday, January 27th. They set a “hold” rating and a $14.00 target price on the stock. Stifel Nicolaus initiated coverage on Orthofix Medical in a report on Tuesday, October 28th. They issued a “buy” rating and a $22.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $17.67.

Orthofix Medical Price Performance

NASDAQ:OFIX opened at $13.04 on Wednesday. The company has a market cap of $516.38 million, a P/E ratio of -5.57 and a beta of 0.78. The firm’s fifty day moving average price is $14.17 and its two-hundred day moving average price is $14.71. Orthofix Medical has a one year low of $10.24 and a one year high of $18.66. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.45 and a quick ratio of 1.38.

Orthofix Medical (NASDAQ:OFIX) last posted its earnings results on Tuesday, February 24th. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.50). The company had revenue of $219.91 million for the quarter, compared to analyst estimates of $218.72 million. Orthofix Medical had a negative return on equity of 20.38% and a negative net margin of 11.21%. Equities analysts expect that Orthofix Medical will post -2.81 earnings per share for the current year.

Insider Buying and Selling at Orthofix Medical

In other Orthofix Medical news, CEO Massimo Calafiore sold 9,797 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $15.21, for a total transaction of $149,012.37. Following the sale, the chief executive officer directly owned 217,237 shares in the company, valued at $3,304,174.77. This represents a 4.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Julie Andrews sold 4,873 shares of the firm’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $14.38, for a total transaction of $70,073.74. Following the completion of the transaction, the chief financial officer directly owned 58,039 shares in the company, valued at approximately $834,600.82. This represents a 7.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 24,270 shares of company stock worth $370,958. 1.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in OFIX. Squarepoint Ops LLC boosted its holdings in shares of Orthofix Medical by 515.6% in the 2nd quarter. Squarepoint Ops LLC now owns 117,666 shares of the medical device company’s stock valued at $1,312,000 after purchasing an additional 98,552 shares in the last quarter. AYAL Capital Advisors Ltd boosted its stake in Orthofix Medical by 74.7% in the second quarter. AYAL Capital Advisors Ltd now owns 943,203 shares of the medical device company’s stock valued at $10,517,000 after buying an additional 403,433 shares in the last quarter. Engine Capital Management LP boosted its stake in Orthofix Medical by 13.6% in the second quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company’s stock valued at $47,406,000 after buying an additional 510,281 shares in the last quarter. Geode Capital Management LLC grew its position in Orthofix Medical by 7.5% in the second quarter. Geode Capital Management LLC now owns 930,252 shares of the medical device company’s stock valued at $10,374,000 after acquiring an additional 64,788 shares during the last quarter. Finally, Bastion Asset Management Inc. acquired a new position in Orthofix Medical during the second quarter worth about $349,000. 89.76% of the stock is currently owned by institutional investors and hedge funds.

More Orthofix Medical News

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Barrington Research cut its price target from $18 to $17 but kept an “outperform” rating, implying continued analyst confidence and roughly ~30% upside from current levels. Read More.
• Positive Sentiment: Management extended its timeline for a 6.5%–7.5% sales CAGR through 2028, citing maturing channel optimization — a signal of sustained top‑line growth ambitions that supports longer‑term upside. Read More.
• Neutral Sentiment: Company filed its Q4 and full‑year 2025 results and provided FY‑2026 guidance and updated three‑year targets (pro forma measures exclude the discontinued M6 product lines) — investors will parse one‑time impacts vs. core trends in the slide deck and call. Read More.
• Negative Sentiment: Reported Q4 results missed consensus on profitability: Orthofix reported an EPS shortfall versus the $0.44 estimate (management reported a miss of roughly $0.50 on the metric) and showed negative net margin/return on equity, pressuring near‑term sentiment. Read More.
• Negative Sentiment: Independent coverage flagged the earnings miss as well: Zacks reports Q4 EPS came in below estimates, reinforcing the view that the quarter underperformed consensus. Read More.
• Negative Sentiment: FY‑2026 revenue guidance was set at $850M–$860M, slightly under the Street’s ~$861.4M consensus — a modest headwind that could cap near‑term upside until execution clarity improves. Read More.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.